---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-036288"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:49:08.687269+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech to present updated Versamune HPV Phase 2 data at ASTRO 2024

## Summary
- Updated IMMUNOCERV Phase 2 data for Versamune® HPV (PDS0101) with chemoradiation in locally advanced cervical cancer accepted for oral presentation at ASTRO 2024.
- Presentation scheduled for Oct 1, 2024, 2:50-3:00 p.m. ET; lead author Dr. Adam Grippin from MD Anderson.
- No specific efficacy results disclosed in this press release; investors await presentation for updated data.

## SEC filing metadata
- accession: 0001140361-24-036288
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036124036288/0001140361-24-036288-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036124036288/ef20033761_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-036288
- JSON: https://secwatch.observer/filing/0001140361-24-036288.json
- Plain text: https://secwatch.observer/filing/0001140361-24-036288.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.